Sugi Predict

Sugi Predict / Compounds / SCHEMBL557540

SCHEMBL557540

SCHEMBL557540

CC(C)(C)OC(=O)CCCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC2 Q92769 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ HDAC8 Q9BY41 1/20 0.35
▸ PRKCA P17252 6/20 0.33
▸ HPGD P15428 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ HTR4 Q13639 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ PSMB8 P28062 1/20 0.31
▸ PSMB5 P28074 1/20 0.31
▸ TPSAB1 Q15661 1/20 0.31
▸ TPSD1 Q9BZJ3 1/20 0.31
▸ TPSG1 Q9NRR2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11920409 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL905426 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL11920413 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL1676918 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL558796 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL25434198 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL905423 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL1510015 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL15196458 0.95 EPHX2 (0.35) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL8740492 0.92 STING1 (0.34) EPHX2KMT2AALDH1A1PSMB8PSMB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118772035-B Method for efficiently preparing fatty diacid derivative and application thereof 合肥亿帆生物制药有限公司 2025-02-28 — — CN disclosed
CN-118772035-A Method for efficiently preparing fatty diacid derivative and application thereof 合肥亿帆生物制药有限公司 2024-10-15 — — CN disclosed
US-11358994-B2 Fatty acid modified human epidermal growth factor SAINT LOUIS UNIVERSITY (US) 2022-06-14 — — US disclosed
CN-111518009-A Fatty acid derivative and synthetic method thereof 鲁南制药集团股份有限公司 2020-08-11 — — CN disclosed
US-20200190157-A1 FATTY ACID MODIFIED HUMAN EPIDERMAL GROWTH FACTOR SAINT LOUIS UNIVERSITY (US) 2020-06-18 — — US disclosed
US-20190112348-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES NOVO NORDISK AS (DK) 2019-04-18 — — US disclosed
US-10259856-B2 Protease stabilized acylated insulin analogues NOVO NORDISK A/S (DK) 2019-04-16 — — US disclosed
WO-2019023295-A1 FATTY ACID MODIFIED HUMAN EPIDERMAL GROWTH FACTOR SAINT LOUIS UNIVERSITY (US) 2019-01-31 — — WO disclosed
US-9688737-B2 Protease stabilized acylated insulin analogues NOVO NORDISK A/S (DK) 2017-06-27 — — US disclosed
EP-2264065-B1 NOVEL INSULIN DERIVATIVES NOVO NORDISK AS (DK) 2017-03-08 — — EP disclosed
EP-1846447-A1 INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2007-10-24 — — EP disclosed
EP-1846446-A1 INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2007-10-24 — — EP disclosed
US-20070129284-A1 Single-chain insulin NOVO NORDISK A/S (DK) 2007-06-07 — — US disclosed
EP-1692168-A1 SINGLE-CHAIN INSULIN NOVO NORDISK A/S (DK) 2006-08-23 — — EP disclosed
US-20060183668-A1 Antidiabetic agents; insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the alpha-amino group of the N-terminal amino acid residue of the B chain or to epsilon-amino group of a Lys residue present in the B chain of parent insulin NOVO NORDISK A/S (DK) 2006-08-17 — — US disclosed
WO-2006082205-A1 INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2006-08-10 — — WO disclosed
WO-2006082204-A1 INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2006-08-10 — — WO disclosed
EP-1660531-A2 NOVEL INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2006-05-31 — — EP disclosed
WO-2005054291-A1 SINGLE-CHAIN INSULIN NOVO NORDISK A/S (DK) 2005-06-16 — — WO disclosed
WO-2005012347-A2 NOVEL INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2005-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200190157-A1 FATTY ACID MODIFIED HUMAN EPIDERMAL GROWTH FACTOR FABP2, FGFR2, FGF2 EPHX2 1129/4885SMN1; SMN2 722/4885KMT2A 3499/4885
US-11358994-B2 Fatty acid modified human epidermal growth factor FABP2, EGFR, HGF EPHX2 917/4885SMN1; SMN2 2392/4885KMT2A 3837/4885
US-20070129284-A1 Single-chain insulin IGF1R, IGFBP1, INSR EPHX2 4770/4885SMN1; SMN2 2115/4885KMT2A 2732/4885
US-20190112348-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES IAPP, IDE, LIPE EPHX2 4491/4885SMN1; SMN2 1083/4885KMT2A 2298/4885
US-10259856-B2 Protease stabilized acylated insulin analogues IAPP, IDE, LIPE EPHX2 4657/4885SMN1; SMN2 1218/4885KMT2A 2426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.